Clinical Trial Closeup

A Drop for DME and AMD

Are clinical investigators close to finding the Holy Grail for retinal disease?

Restoring Cell Function to Block VEGF

Integrin peptide therapy Luminate shows potential of extending DME treatment.  

FA Insert Delivers At 12 Months

Top-line results through 12 months show sustained effect of three-year insert for
noninfectious posterior uveitis.

Can a Gene Vector Work for Long Term?

Lentiviral vector expresses protein for up to four years in trial.

Can Brimonidine Reduce GA Progression?

Phase IIA trial shows potential of its neuroprotective properties for retinal disease.

Drugability of the Suprachoroidal Space

Phase II trial shows Clearside’s CLS-TA safe and effective in noninfectious uveitis.

APL-2’s Role in Blocking the GA Cascade

By inhibiting complement factor C3, Apellis bets it can prevent inflammation in advanced dry AMD

SPK-RPE65 Gene ‘Augmentation’

This biological agent targets mutations in genes that mediate visual transduction.

AKB-9778 as an Adjunct to Anti-VEGF

A deeper dive into how this Tie-2 activator stabilizes the retinal vasculature.

Impact of the OHR-102 IMPACT Data

A closer look at combination therapy and CNV.


Lead investigator provides details on parallel trials of lampalizumab.